Sai Life Sciences Expands R&D Facility to Boost Global Drug Development

Sai Life Sciences is set to significantly increase its capabilities with the groundbreaking of a new Process R&D Center at its Hyderabad campus. This expansion aims to double its current R&D capacity by 2026, enhancing its offerings in peptide and oligo intermediates development, formulation innovation, and early-phase clinical supplies. This strategic move highlights the company’s commitment to accelerating drug development in collaboration with global pharmaceutical and biotech innovators. 

Sai Life Sciences, a prominent CRDMO, partners with global pharma and biotech companies to hasten the discovery and development of innovative medicines. The expansion of their Hyderabad facility underpins the growing demand for rapid, end-to-end drug development solutions. With its new 100,000 sq. ft. R&D center, Sai Life Sciences is enhancing its scientific capabilities and embracing sustainability with a green building design. This development is poised to meet the increasing need for larger clinical-scale projects and streamline the drug development pipeline. Designed to support both FTE and DPC models, the center offers flexible collaboration options, ensuring scientific excellence and execution agility for its partners.